Metlinka 50 Mg/850 Mg

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka 50 Mg/850 Mg, is a Biguanide/DPP‑4 inhibitor presented as an 850 mg/50 mg oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, providing combined glucose‑lowering effects through complementary mechanisms.

GNH USA supplies Metlinka 50 Mg/850 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Metlinka 50 Mg/850 Mg is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

Type 2 diabetes mellitus: improves overall glycemic control when added to metformin monotherapy. Adults with inadequate HbA1c reduction on metformin alone: provides additional DPP‑4 inhibition to further lower blood glucose. Patients requiring a weight‑neutral regimen: offers glucose lowering without promoting weight gain.

Metlinka may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory symptoms: nasopharyngitis or sore throat. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Metlinka, clinicians should consider several precautionary measures to ensure patient safety.

Renal function: assess eGFR before initiating therapy and monitor periodically. Hepatic impairment: use with caution and evaluate liver enzymes regularly. Lactic acidosis risk: avoid in patients with conditions that predispose to hypoxia or severe infection. Pregnancy and lactation: safety not established; discuss potential risks with the healthcare provider. Drug interactions: review concomitant medications for possible pharmacokinetic or pharmacodynamic effects. Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Metlinka can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase sitagliptin plasma concentrations. - Co‑administration with metformin‑containing iodinated contrast agents can raise the risk of lactic acidosis. - Combination with sulfonylureas or insulin may cause severe hypoglycemia. - High‑dose alcohol intake may exacerbate metformin‑related toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin, requiring dose adjustment. - Beta‑blockers: can mask typical hypoglycemia symptoms, necessitating closer glucose monitoring. - ACE inhibitors or ARBs: concurrent use may warrant periodic renal function assessment.